PD-1 INHIBITION CAN BE COMBINED WITH IL-12 IN SUBJECTS WITH RECURRENT GLIOBLASTOMA

被引：0
|
作者：
Chiocca, Ennio [1 ]
Lukas, Rimas [2 ]
Rao, Ganesh [3 ]
Buck, Jill [4 ]
Demars, Nathan [4 ]
Smith, Amy [4 ]
Miao, John [4 ]
Zhou, John [4 ]
Gelb, Arnold [4 ]
Cooper, Laurence [4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA
[2] Northwestern Med, Chicago, IL USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Ziopharm Oncol Inc, Boston, MA USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-25
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [21] Advanced glioblastoma immunotherapy: Attenuated herpes oncolytic virus armed with anti-PD-1 antibody and IL-12
    Wang, Lei
    Zhou, Xusha
    Chen, Xiaoqing
    Liu, Yuanyuan
    Zheng, Yanxin
    Yan, Runbin
    Liu, Yonghong
    Zhao, Jing
    Zhou, Grace Guoying
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition
    Lee, Jay M.
    Tsuboi, Masahiro
    Kim, Edward S.
    Mok, Tony S. K.
    Garrido, Pilar
    FUTURE ONCOLOGY, 2022, 18 (27) : 3085 - 3100
  • [23] Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma
    Thummalapalli, Rohit
    Heumann, Thatcher
    Stein, Julie
    Khan, Sarah
    Priemer, David S.
    Duffield, Amy S.
    Laterra, John
    Couzi, Rima
    Lim, Michael
    Holdhoff, Matthias
    CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 508 - 514
  • [24] A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
    Chiu, Daniel
    Qi, Jingjing
    Thin, Tin Htwe
    Garcia-Barros, Monica
    Lee, Brian
    Hahn, Mary
    Mandeli, John
    Belani, Puneet
    Nael, Kambiz
    Rashidipour, Omid
    Ghatan, Saadi
    Hadjipanayis, Constantinos G.
    Yong, Raymund L.
    Germano, Isabelle M.
    Brody, Rachel
    Tsankova, Nadejda M.
    Gnjatic, Sacha
    Kim-Schulze, Seunghee
    Hormigo, Adilia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (01): : 130 - 139
  • [25] Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?
    Arrieta, Victor A.
    Iwamoto, Fabio
    Lukas, Rimas V.
    Sachdev, Sean
    Rabadan, Raul
    Sonabend, Adam M.
    JOURNAL OF NEUROSURGERY, 2020, 132 (05) : 1667 - 1672
  • [26] CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1
    Yin, Peng
    Liu, Xin
    Mansfield, Aaron S.
    Harrington, Susan M.
    Li, Yinghua
    Yan, Yiyi
    Dong, Haidong
    ONCOTARGET, 2016, 7 (43) : 70223 - 70231
  • [27] PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
    Post, Cathalijne C. B.
    Westermann, Anneke M.
    Bosse, Tjalling
    Creutzberg, Carien L.
    Kroep, Judith R.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 152
  • [28] Cell Based IL12 Immunomodulation Combined with PD-1 Inhibition Generates Local and Abscopal Immune Activation to Eradicate Metastatic Pancreatic Cancer
    Veiseh, Omid
    MOLECULAR THERAPY, 2023, 31 (04) : 496 - 496
  • [29] Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells
    Quatrini, Linda
    Vacca, Paola
    Tumino, Nicola
    Besi, Francesca
    Di Pace, Anna Laura
    Scordamaglia, Francesca
    Martini, Stefania
    Munari, Enrico
    Mingari, Maria Cristina
    Ugolini, Sophie
    Moretta, Lorenzo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (01) : 349 - 360
  • [30] PD-L1/PD-1 Axis in Glioblastoma Multiforme
    Litak, Jakub
    Mazurek, Marek
    Grochowski, Cezary
    Kamieniak, Piotr
    Rolinski, Jacek
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)
12345